Name | No. | For Patients with | Purpose |
---|---|---|---|
EPIK-B5 | 21-32 | HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
The purpose of this study is to obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
DSSG Group: Breast
KEYNOTE-B49
Name | No. | For Patients with | Purpose |
---|---|---|---|
KEYNOTE-B49 | 21-31 | Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer |
To assess the safety and efficacy of pembrolizumab plus the investigator’s choice of chemotherapy compared to placebo plus the investigator’s choice of chemotherapy |
lidERA Breast Cancer/ GO42784/ TRIO 045
Name | No. | For Patients with | Purpose |
---|---|---|---|
lidERA Breast Cancer/ GO42784/ TRIO 045 | 21-04 | with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer |
to evaluate the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice |
SASCIA
Name | No. | For Patients with | Purpose |
---|---|---|---|
SASCIA | 20-24 | Primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment |
This study is a phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA |
DESTINY-Breast05
Name | No. | For Patients with | Purpose |
---|---|---|---|
DESTINY-Breast05 | 21-15 | HER2-positive primary breast cancer who do not achieve complete response after appropriate neoadjuvant therapy and are at higher risk of disease recurrence. |
This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy. |
Proteomics / Molecular Breast
Name | No. | For Patients with | Purpose |
---|---|---|---|
Proteomics / Molecular Breast | 09-07 | Breast cancer |
The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells. |